adplus-dvertising
Connect with us

Investment

RBC taps into biotech surge, investing in new Lumira venture fund

Published

 on

Royal Bank of Canada is backing the country’s largest life sciences venture capital fund in two decades, making it one of the few Bay Street institutions to invest in the surging domestic sector.

RBC’s undisclosed investment with Toronto-based Lumira Ventures, which has financed some of Canada’s most valuable biotechnology companies, is “not a one-off and is part of a broader strategy” by Canada’s largest bank to support the sector, said Anthony Mouchantaf, director with RBC’s technology and innovation banking group.

Mr. Mouchantaf offered few details but said “there will be an investment component and a more dedicated fund-of-funds strategy” that will see RBC back other biotech funds. “It’s a long-term bet and commitment for us. Our goal is that we play a role … in helping get to another generation of breakout Canadian and North American companies.”

RBC’s move follows a record year in 2020 for private and public fundraising by Canadian biotech companies, including the three largest initial public offerings ever by domestic drug developers: AbCellera Biologics Inc. , Repare Therapeutics Inc. and Fusion Pharmaceuticals Inc.

The addition of RBC to Lumira’s investor ranks is big news for Canadian biotech. For years, financiers and companies have attempted to entice Canadian asset managers outside Quebec – where support has been strong – to back the sector.

Previously the only bite was from Canada Pension Plan Investment Board, which invested US$20-million in Fusion Pharmaceuticals months before the Hamilton cancer therapy developer’s IPO in June, 2020. That, however, was part of a global toe-in-the-water approach by CPPIB to fund emerging sectors and not part of a Canadian-focused effort.

“The great thing about RBC coming into the asset class is that it will provide more depth to our local funds and they can then take bigger stakes, bolder moves and be more inclined to” create companies, said Geneviève Guertin, vice-president of investments, life sciences, with Quebec’s Fonds de solidarité FTQ (FondsFTQ), a leading backer of the sector.

Lumira is raising its fourth fund with a target of reaching US$200-million to back Canadian and U.S. drug and medical technology developers. It is about three-quarters of the way to its goal and is already larger than any Canadian biotech fund since the early 2000s. (Lumira raised $178-million for its previous fund in 2017.) Managing general partner Peter van der Velden said an unidentified Chinese pharmaceutical company has also invested, and that most additional capital would likely come from outside Canada.

The rest of Canada’s coterie of biotech venture capital firms – CTI Life Sciences, Genesys Capital and Amplitude Venture Capital – are also raising funds. San Francisco’s Versant Ventures is expected to launch a sequel to its Canada-focused Voyageur fund this year.

Lumira, once known as MDS Capital, struggled for years under previous owner MDS Laboratory Services, before a 2007 management buyout and rechristening. Mr. van der Velden said the goal when Lumira raised its first postspinout funds in 2012 was to create companies worth US$1-billion. That was “a big, hairy, audacious idea,” as no new Canadian company had hit that threshold in years, he said. Two Lumira companies – Zymeworks Inc. and Aurinia Pharmaceuticals Inc. – have since reached that level.

Lumira has had a solid run lately: Aurinia got regulatory approval last month to sell its lupus drug in the U.S. and is aiming to become one of the few Canadian developers to become a fully integrated drug company. Lumira has realized returns of five to 10 times its investment in Aurinia.

Two Lumira-backed U.S. companies, Bardy Diagnostics and Engage Therapeutics, have sold for hundreds of millions of dollars each since June, and Toronto digital health care company Think Research Corp. went public in December.

“Financial returns are why we are in business,” Lumira managing director Gerry Brunk said. “But those result in concrete, meaningful impact on patients around the world.”

Lumira’s returns rank among the top quartile of all North American venture funds. “Back in the day, we backed [Lumira] because we saw its potential to become a flagship Canadian venture capital franchise,” Ms. Guertin said. “We’re proud because they did deliver … very good returns.”

Despite that, most of Lumira’s Canadian institutional backing has come from Quebec investors, including FondsFTQ, Caisse de dépôt et placement du Québec, Fondaction and Teralys Capital. Its investors also include Ontario fund-of-funds managers Northleaf Capital and Kensington Capital Partners, as well as Vancouver City Savings Credit Union.

“If it wasn’t for those Quebec-based pension plans we wouldn’t exist,” Mr. van der Velden said.

Ms. Guertin said: “It has always puzzled us that other [Canadian] institutions seem to be a bit more afraid of the asset class.”

Source:- The Globe and Mail

Source link

Continue Reading

Economy

S&P/TSX gains almost 100 points, U.S. markets also higher ahead of rate decision

Published

 on

 

TORONTO – Strength in the base metal and technology sectors helped Canada’s main stock index gain almost 100 points on Friday, while U.S. stock markets climbed to their best week of the year.

“It’s been almost a complete opposite or retracement of what we saw last week,” said Philip Petursson, chief investment strategist at IG Wealth Management.

In New York, the Dow Jones industrial average was up 297.01 points at 41,393.78. The S&P 500 index was up 30.26 points at 5,626.02, while the Nasdaq composite was up 114.30 points at 17,683.98.

The S&P/TSX composite index closed up 93.51 points at 23,568.65.

While last week saw a “healthy” pullback on weaker economic data, this week investors appeared to be buying the dip and hoping the central bank “comes to the rescue,” said Petursson.

Next week, the U.S. Federal Reserve is widely expected to cut its key interest rate for the first time in several years after it significantly hiked it to fight inflation.

But the magnitude of that first cut has been the subject of debate, and the market appears split on whether the cut will be a quarter of a percentage point or a larger half-point reduction.

Petursson thinks it’s clear the smaller cut is coming. Economic data recently hasn’t been great, but it hasn’t been that bad either, he said — and inflation may have come down significantly, but it’s not defeated just yet.

“I think they’re going to be very steady,” he said, with one small cut at each of their three decisions scheduled for the rest of 2024, and more into 2025.

“I don’t think there’s a sense of urgency on the part of the Fed that they have to do something immediately.

A larger cut could also send the wrong message to the markets, added Petursson: that the Fed made a mistake in waiting this long to cut, or that it’s seeing concerning signs in the economy.

It would also be “counter to what they’ve signaled,” he said.

More important than the cut — other than the new tone it sets — will be what Fed chair Jerome Powell has to say, according to Petursson.

“That’s going to be more important than the size of the cut itself,” he said.

In Canada, where the central bank has already cut three times, Petursson expects two more before the year is through.

“Here, the labour situation is worse than what we see in the United States,” he said.

The Canadian dollar traded for 73.61 cents US compared with 73.58 cents US on Thursday.

The October crude oil contract was down 32 cents at US$68.65 per barrel and the October natural gas contract was down five cents at US$2.31 per mmBTU.

The December gold contract was up US$30.10 at US$2,610.70 an ounce and the December copper contract was up four cents US$4.24 a pound.

— With files from The Associated Press

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Economy

S&P/TSX composite down more than 200 points, U.S. stock markets also fall

Published

 on

 

TORONTO – Canada’s main stock index was down more than 200 points in late-morning trading, weighed down by losses in the technology, base metal and energy sectors, while U.S. stock markets also fell.

The S&P/TSX composite index was down 239.24 points at 22,749.04.

In New York, the Dow Jones industrial average was down 312.36 points at 40,443.39. The S&P 500 index was down 80.94 points at 5,422.47, while the Nasdaq composite was down 380.17 points at 16,747.49.

The Canadian dollar traded for 73.80 cents US compared with 74.00 cents US on Thursday.

The October crude oil contract was down US$1.07 at US$68.08 per barrel and the October natural gas contract was up less than a penny at US$2.26 per mmBTU.

The December gold contract was down US$2.10 at US$2,541.00 an ounce and the December copper contract was down four cents at US$4.10 a pound.

This report by The Canadian Press was first published Sept. 6, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Economy

S&P/TSX composite up more than 150 points, U.S. stock markets also higher

Published

 on

 

TORONTO – Canada’s main stock index was up more than 150 points in late-morning trading, helped by strength in technology, financial and energy stocks, while U.S. stock markets also pushed higher.

The S&P/TSX composite index was up 171.41 points at 23,298.39.

In New York, the Dow Jones industrial average was up 278.37 points at 41,369.79. The S&P 500 index was up 38.17 points at 5,630.35, while the Nasdaq composite was up 177.15 points at 17,733.18.

The Canadian dollar traded for 74.19 cents US compared with 74.23 cents US on Wednesday.

The October crude oil contract was up US$1.75 at US$76.27 per barrel and the October natural gas contract was up less than a penny at US$2.10 per mmBTU.

The December gold contract was up US$18.70 at US$2,556.50 an ounce and the December copper contract was down less than a penny at US$4.22 a pound.

This report by The Canadian Press was first published Aug. 29, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending